SAN DIEGO & DUBLIN–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NBRV&src=ctag” target=”_blank”gt;$NBRVlt;/agt; lt;a href=”https://twitter.com/hashtag/ClassAction?src=hash” target=”_blank”gt;#ClassActionlt;/agt;–Shareholder rights law firm Robbins
Arroyo LLP reminds investors that a purchaser of Nabriva
Therapeutics plc filed a class action complaint against Nabriva
Therapeutics plc (NASDAQ: NBRV) for alleged violations of the Securities
Exchange Act of 1934 between November 1, 2018 and April 30, 2019.
Nabriva is a biopharmaceutical company that develops novel
anti-infective agents to treat serious infections. One of its product
candidates is CONTEPO, an epoxide antibiotic developed by Zavante
Therapeutics, which Nabriva acquired in July 2018.
View this information on the law firm’s Shareholder Rights Blog:
https://www.robbinsarroyo.com/nabriva-therapeutics-may-19/
Nabriva Accused of Misleading Investors
According to the complaint, in November 2018, Nabriva announced the
submission of its New Drug Application (“NDA”) to the U.S. Food and Drug
Administration (“FDA”) for Intravenous CONTEPO. In the following months,
Nabriva released press releases touting the progress of the NDA through
the approval process. However, Nabriva failed to disclose quality
control issues relating to its manufacturers’ practices. In April 2019,
Nabriva revealed that the FDA would not approve the NDA due to “issues
related to facility inspections and manufacturing deficiencies at one of
Nabriva’s contract manufacturers.” On this news, the Nabriva’s share
price fell over 27% to close at $2.17 per share on May 1, 2019.
Nabriva Shareholders Have Legal Options
Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leo Kandinov at (800)
350-6003, [email protected]
or via the shareholder
information form on the firm’s website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San
Diego, CA 92122
[email protected]
(619)
525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
